{"url":"https://lda.senate.gov/api/v1/filings/75caa813-99e6-41a1-b8de-e2de71a6bc50/","filing_uuid":"75caa813-99e6-41a1-b8de-e2de71a6bc50","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2022,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/75caa813-99e6-41a1-b8de-e2de71a6bc50/print/","filing_document_content_type":"text/html","income":null,"expenses":"710000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Samantha Ventimiglia","dt_posted":"2022-10-14T15:52:14-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"50 Northern Avenue","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Boston","registrant_state":"MA","registrant_zip":"02210","registrant":{"id":40027242,"url":"https://lda.senate.gov/api/v1/registrants/40027242/","house_registrant_id":39888,"name":"VERTEX PHARMACEUTICALS INCORPORATED","description":"Global biotechnology company","address_1":"50 Northern Avenue","address_2":null,"address_3":null,"address_4":null,"city":"Boston","state":"MA","state_display":"Massachusetts","zip":"02210","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SAMANTHA VENTIMIGLIA","contact_telephone":"+1 202-264-3511","dt_updated":"2026-07-29T12:53:27.346758-04:00"},"client":{"id":188223,"url":"https://lda.senate.gov/api/v1/clients/188223/","client_id":48,"name":"VERTEX PHARMACEUTICALS INCORPORATED","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-02-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as \"Sickle Cell Disease Awareness Month\".","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":64250,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104352,"prefix":null,"prefix_display":null,"first_name":"KWAMME","nickname":null,"middle_name":null,"last_name":"ANDERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53020,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"VENTIMIGLIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":104352,"prefix":null,"prefix_display":null,"first_name":"KWAMME","nickname":null,"middle_name":null,"last_name":"ANDERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":64250,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53020,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"VENTIMIGLIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report \"Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action\" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64250,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104352,"prefix":null,"prefix_display":null,"first_name":"KWAMME","nickname":null,"middle_name":null,"last_name":"ANDERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53020,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"VENTIMIGLIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - \"PREVENT Pandemics Act.\"","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":53020,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"VENTIMIGLIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":64250,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104352,"prefix":null,"prefix_display":null,"first_name":"KWAMME","nickname":null,"middle_name":null,"last_name":"ANDERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}